Bioneer Corporation
Financials
Valuation Metrics
Bioneer Corporation's Market Cap is ₩1768B. At end of 2025 it was ₩3291B. Ranked #860 of 2,410 in KR market (top 36%), #394 of 1,631 on KOSDAQ (top 24%), #97 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.80B KRW | KR#860/2,410 Sec#97/231 |
| Revenue | 345.88B KRW | KR#774/2,410 Sec#35/231 |
| Net Income | -3.67B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 369.32B KRW | KR#915/2,410 Sec#56/231 |
| Net Assets | 217.58B KRW | KR#898/2,410 Sec#63/231 |
| Employees | 392 | KR#622/2,410 Sec#54/231 |
| Value | ||
| P/B | 0.81x | KR#1,353/2,410 Sec#81/231 |
| P/S | 0.51x | KR#998/2,410 Sec#48/231 |
| EV/EBITDA | 38.08x | KR#1,293/2,410 Sec#83/231 |
| FCF Yield | 2.01% | KR#1,065/2,410 Sec#71/231 |
| Profitability | ||
| ROE | -1.69% | KR#1,663/2,410 Sec#114/231 |
| ROA | -0.99% | KR#1,677/2,410 Sec#116/231 |
| Op. Margin | 1.80% | KR#1,410/2,410 Sec#98/231 |
| Revenue Growth | 15.87% | KR#654/2,410 Sec#61/231 |
| Financial Health | ||
| Debt Ratio | 69.74% | KR#1,212/2,410 Sec#148/231 |
| Total Debt | 104.64B KRW | KR#708/2,410 Sec#44/231 |
| FCF | 3.55B KRW | KR#986/2,410 Sec#71/231 |
| Cash | 43.98B KRW | KR#799/2,410 Sec#49/231 |
| Current Ratio | 2.00x | KR#866/2,410 Sec#98/231 |
| Net Debt/EBITDA | 9.73x | KR#1,212/2,410 Sec#88/231 |
| Dividend | ||
| Div. Yield | 5.31% | KR#288/2,410 Sec#9/231 |
| Performance | ||
| 1Y Return | -55.81% | KR#2,024/2,410 Sec#179/231 |
| 1M Return | -20.07% | KR#1,859/2,410 Sec#183/231 |
| From 52W High | -56.20% | KR#1,441/2,410 Sec#116/231 |
| 1Y MDD | -62.65% | KR#1,590/2,410 Sec#128/231 |
| Trading | ||
| Volume | 66,580 shares | KR#663/2,410 Sec#69/231 |
| Trading Value | 454.0M KRW | KR#699/2,410 Sec#72/231 |
| Foreign Own. | 4.42% | KR#963/2,410 Sec#84/231 |
| Per Share | ||
| EPS | -142 KRW | KR—/2,410 Sec—/231 |
| BPS | 8,430 KRW | KR#1,106/2,410 Sec#77/231 |
Company Info
Established in 1992 as the first researcher startup from the Korea Research Institute of Bioscience and Biotechnology, the company is a genetic engineering specialist listed on KOSDAQ in 2005. It operates diverse bio-healthcare businesses, including life science research equipment, reagents, molecular diagnostics, and synthetic biology. The company is developing a next-generation molecular diagnostics platform and a SAMiRNA new drug development platform to pursue global market entry. It also reinvests in research and development and expands its business portfolio through technological innovation. Bioneer is headquartered in Yuseong-gu, Daejeon.